메뉴 건너뛰기




Volumn 11, Issue 1, 2014, Pages 166-176

Tardive Dyskinesia: Therapeutic Options for an Increasingly Common Disorder

Author keywords

Amantadine; Levetiracetam; Prevalence; Reversibility; Tardive dyskinesia; Tetrabenazine

Indexed keywords

AMANTADINE; BOTULINUM TOXIN; CLONAZEPAM; ETIRACETAM; GINKGO BILOBA EXTRACT; NEUROLEPTIC AGENT; PIRACETAM; PROPRANOLOL; PYRIDOXINE; TETRABENAZINE;

EID: 84893138322     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-013-0222-5     Document Type: Review
Times cited : (91)

References (117)
  • 2
    • 33646944093 scopus 로고    scopus 로고
    • Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?
    • Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 2006;21: 589-598.
    • (2006) Mov Disord , vol.21 , pp. 589-598
    • Tarsy, D.1    Baldessarini, R.J.2
  • 3
    • 77949525751 scopus 로고    scopus 로고
    • Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug
    • Li CR, Chung YC, Park TW, et al. Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug. World J Biol Psychiatry 2009;10: 919-924.
    • (2009) World J Biol Psychiatry , vol.10 , pp. 919-924
    • Li, C.R.1    Chung, Y.C.2    Park, T.W.3
  • 4
    • 0032731975 scopus 로고    scopus 로고
    • Possible tardive dystonia resulting from clozapine therapy
    • Molho ES, Factor SA. Possible tardive dystonia resulting from clozapine therapy. Mov Disord 1999;14: 873-874.
    • (1999) Mov Disord , vol.14 , pp. 873-874
    • Molho, E.S.1    Factor, S.A.2
  • 5
    • 33645293206 scopus 로고    scopus 로고
    • Drug Insight: from disturbed motility to disordered movement-a review of the clinical benefits and medicolegal risks of metoclopramide
    • Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug Insight: from disturbed motility to disordered movement-a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol 2006;3: 138-148.
    • (2006) Nat Clin Pract Gastroenterol Hepatol , vol.3 , pp. 138-148
    • Pasricha, P.J.1    Pehlivanov, N.2    Sugumar, A.3    Jankovic, J.4
  • 6
    • 85114484996 scopus 로고    scopus 로고
    • An update on tardive dyskinesia: from phenomenology to treatment
    • Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov 2013;3.
    • (2013) Tremor Other Hyperkinet Mov , vol.3
    • Waln, O.1    Jankovic, J.2
  • 7
    • 84881305397 scopus 로고    scopus 로고
    • Evidence-based guideline: Treatment of tardive syndromes: Report of the Guideline Development Subcommittee of the American Academy of Neurology
    • Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA. Evidence-based guideline: Treatment of tardive syndromes: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2013;8: 463-469.
    • (2013) Neurology , vol.8 , pp. 463-469
    • Bhidayasiri, R.1    Fahn, S.2    Weiner, W.J.3    Gronseth, G.S.4    Sullivan, K.L.5    Zesiewicz, T.A.6
  • 9
    • 0020404121 scopus 로고
    • Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs
    • Burke RE, Fahn S, Jankovic J, Marsden CD, Lang AE, Gollomp S, et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology 1982;32: 1335-1346.
    • (1982) Neurology , vol.32 , pp. 1335-1346
    • Burke, R.E.1    Fahn, S.2    Jankovic, J.3    Marsden, C.D.4    Lang, A.E.5    Gollomp, S.6
  • 11
    • 0023508569 scopus 로고
    • Life-threatening tardive dyskinesia caused by metoclopramide
    • Samie MR, Dannenhoffer MA, Rozek S. Life-threatening tardive dyskinesia caused by metoclopramide. Mov Disord 1987;2: 125-29.
    • (1987) Mov Disord , vol.2 , pp. 125-129
    • Samie, M.R.1    Dannenhoffer, M.A.2    Rozek, S.3
  • 12
    • 21244461370 scopus 로고    scopus 로고
    • Neuroleptic-Induced tardive dyskinesia variants
    • S. A. Factor, A. E. Lang, and W. J. Weiner (Eds.), Malden, MA: Blackwell Futura
    • Skidmore FW, Weiner, WJ, Burke, R. Neuroleptic-Induced tardive dyskinesia variants. In: Factor SA, Lang AE, Weiner WJ (eds) Drug induced movement disorders. Blackwell Futura, Malden, MA, 2005, pp. 257-284.
    • (2005) Drug Induced Movement Disorders , pp. 257-284
    • Skidmore, F.W.1    Weiner, W.J.2    Burke, R.3
  • 13
    • 0026799190 scopus 로고
    • Tardive dyskinesia in elderly psychiatric patients: a 5-year study
    • Yassa R, Nastase C, Dupont D, Thibeau M. Tardive dyskinesia in elderly psychiatric patients: a 5-year study. Am J Psychiatry 1992;149: 1206-1211.
    • (1992) Am J Psychiatry , vol.149 , pp. 1206-1211
    • Yassa, R.1    Nastase, C.2    Dupont, D.3    Thibeau, M.4
  • 14
    • 0029023056 scopus 로고
    • Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients
    • Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995;52: 756-765.
    • (1995) Arch Gen Psychiatry , vol.52 , pp. 756-765
    • Jeste, D.V.1    Caligiuri, M.P.2    Paulsen, J.S.3
  • 15
    • 73949099769 scopus 로고    scopus 로고
    • Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis
    • Tenback DE, van Harten PN, van Os J. Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis. Mov Disord 2009;24: 2309-2315.
    • (2009) Mov Disord , vol.24 , pp. 2309-2315
    • Tenback, D.E.1    van Harten, P.N.2    van Os, J.3
  • 16
    • 8744231989 scopus 로고    scopus 로고
    • Ethnicity and the course of tardive dyskinesia in outpatients presenting to the motor disorders clinic at the Maryland psychiatric research center
    • Wonodi I, Adami HM, Cassady SL, Sherr JD, Avila MT, Thaker GK. Ethnicity and the course of tardive dyskinesia in outpatients presenting to the motor disorders clinic at the Maryland psychiatric research center. J Clin Psychopharmacol 2004;24: 592-598.
    • (2004) J Clin Psychopharmacol , vol.24 , pp. 592-598
    • Wonodi, I.1    Adami, H.M.2    Cassady, S.L.3    Sherr, J.D.4    Avila, M.T.5    Thaker, G.K.6
  • 18
    • 0025980669 scopus 로고
    • The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study
    • Ganzini L, Heintz RT, Hoffman WF, Casey DE. The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study. Arch Gen Psychiatry 1991;48: 259-263.
    • (1991) Arch Gen Psychiatry , vol.48 , pp. 259-263
    • Ganzini, L.1    Heintz, R.T.2    Hoffman, W.F.3    Casey, D.E.4
  • 19
  • 21
    • 84891020562 scopus 로고    scopus 로고
    • Tardive dyskinesia
    • S. A. Factor, A. E. Lang, and W. J. Weiner (Eds.), Malden, MA: Blackwell Futura
    • Hyde TM, Apud JA, Fisher WC, Egan MF. Tardive dyskinesia. In: Factor SA, Lang AE, Weiner WJ (eds) Drug induced movement disorders. Blackwell Futura, Malden, MA, 2005, pp. 213-256.
    • (2005) Drug Induced Movement Disorders , pp. 213-256
    • Hyde, T.M.1    Apud, J.A.2    Fisher, W.C.3    Egan, M.F.4
  • 22
    • 0028856570 scopus 로고
    • Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients
    • Chatterjee A, Chakos M, Koreen A, et al. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry 1995;152: 1724-1729.
    • (1995) Am J Psychiatry , vol.152 , pp. 1724-1729
    • Chatterjee, A.1    Chakos, M.2    Koreen, A.3
  • 23
    • 0017694957 scopus 로고
    • Spontaneous buccolinguofacial dyskinesia in the elderly
    • Delwaide PJ, Desseilles M. Spontaneous buccolinguofacial dyskinesia in the elderly. Acta Neurol Scand 1977;56: 256-262.
    • (1977) Acta Neurol Scand , vol.56 , pp. 256-262
    • Delwaide, P.J.1    Desseilles, M.2
  • 24
    • 0015364024 scopus 로고
    • Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine
    • Kazamatsuri H, Chien C, Cole JO. Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine. Arch Gen Psychiatry 1972;27: 95-99.
    • (1972) Arch Gen Psychiatry , vol.27 , pp. 95-99
    • Kazamatsuri, H.1    Chien, C.2    Cole, J.O.3
  • 25
    • 0015362534 scopus 로고
    • Treatment of tardive dyskinesia. II. Short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate
    • Kazamatsuri H, Chien C, Cole JO. Treatment of tardive dyskinesia. II. Short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate. Arch Gen Psychiatry 1972;27: 100-103.
    • (1972) Arch Gen Psychiatry , vol.27 , pp. 100-103
    • Kazamatsuri, H.1    Chien, C.2    Cole, J.O.3
  • 26
    • 33846837063 scopus 로고    scopus 로고
    • Tardive dyskinesia: eliminated, forgotten, or overshadowed?
    • Remington G. Tardive dyskinesia: eliminated, forgotten, or overshadowed? Curr Opin Psychiatry 2007;20: 131-137.
    • (2007) Curr Opin Psychiatry , vol.20 , pp. 131-137
    • Remington, G.1
  • 27
    • 84893154206 scopus 로고    scopus 로고
    • Food and Drug Administration, Center for Drug Evaluation and Research
    • Kaplan S. Metoclopramide: drug use data review. memorandum. Food and Drug Administration, Center for Drug Evaluation and Research, 2005.
    • (2005) Metoclopramide: Drug use data review
    • Kaplan, S.1
  • 28
    • 0020054615 scopus 로고
    • Tardive dyskinesia: prevalence and risk factors, 1959 to 1979
    • Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 1982;39: 473-481.
    • (1982) Arch Gen Psychiatry , vol.39 , pp. 473-481
    • Kane, J.M.1    Smith, J.M.2
  • 29
    • 0026666282 scopus 로고
    • Gender differences in tardive dyskinesia: a critical review of the literature
    • Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 1992;18: 701-715.
    • (1992) Schizophr Bull , vol.18 , pp. 701-715
    • Yassa, R.1    Jeste, D.V.2
  • 31
    • 0027264874 scopus 로고
    • Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications
    • Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry 1993;54: 133-139.
    • (1993) J Clin Psychiatry , vol.54 , pp. 133-139
    • Glazer, W.M.1    Morgenstern, H.2    Doucette, J.T.3
  • 32
    • 15844410325 scopus 로고    scopus 로고
    • Incidence and correlates of tardive dyskinesia in first episode of schizophrenia
    • Chakos MH, Alvir JM, Woerner MG, et al. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry 1996;53: 313-319.
    • (1996) Arch Gen Psychiatry , vol.53 , pp. 313-319
    • Chakos, M.H.1    Alvir, J.M.2    Woerner, M.G.3
  • 33
    • 0030819935 scopus 로고    scopus 로고
    • The emerging role of clozapine in the treatment of movement disorders
    • Factor SA, Friedman JH. The emerging role of clozapine in the treatment of movement disorders. Mov Disord 1997;12: 483-496.
    • (1997) Mov Disord , vol.12 , pp. 483-496
    • Factor, S.A.1    Friedman, J.H.2
  • 34
    • 84893033262 scopus 로고    scopus 로고
    • A call for caution in the use of antipsychotic drugs
    • Friedman RA. A call for caution in the use of antipsychotic drugs. New York Times, 2012.
    • (2012) New York Times
    • Friedman, R.A.1
  • 35
    • 84870603148 scopus 로고    scopus 로고
    • National trends in the office-based treatment of children, adolescents, and adults with antipsychotics
    • Olfson M, Blanco C, Liu SM, Wang S, Correll CU. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry 2012;69: 1247-1256.
    • (2012) Arch Gen Psychiatry , vol.69 , pp. 1247-1256
    • Olfson, M.1    Blanco, C.2    Liu, S.M.3    Wang, S.4    Correll, C.U.5
  • 36
    • 40349094467 scopus 로고    scopus 로고
    • Tardive dyskinesia and new antipsychotics
    • Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008;21: 151-156.
    • (2008) Curr Opin Psychiatry , vol.21 , pp. 151-156
    • Correll, C.U.1    Schenk, E.M.2
  • 37
    • 80053459019 scopus 로고    scopus 로고
    • Long-stay psychiatric patients: a prospective study revealing persistent antipsychotic-induced movement disorder
    • Bakker PR, de Groot IW, van Os J, van Harten PN. Long-stay psychiatric patients: a prospective study revealing persistent antipsychotic-induced movement disorder. PLoS One 2011;6: e25588.
    • (2011) PLoS One , vol.6
    • Bakker, P.R.1    de Groot, I.W.2    van Os, J.3    van Harten, P.N.4
  • 38
    • 53949112680 scopus 로고    scopus 로고
    • Extrapyramidal side-effects of antipsychotics in a randomised trial
    • Miller DD, Caroff SN, Davis SM, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry 2008;193: 279-288.
    • (2008) Br J Psychiatry , vol.193 , pp. 279-288
    • Miller, D.D.1    Caroff, S.N.2    Davis, S.M.3
  • 39
    • 33749321169 scopus 로고    scopus 로고
    • Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)
    • Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63: 1079-1087.
    • (2006) Arch Gen Psychiatry , vol.63 , pp. 1079-1087
    • Jones, P.B.1    Barnes, T.R.2    Davies, L.3
  • 40
    • 77951072007 scopus 로고    scopus 로고
    • Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study
    • Woods SW, Morgenstern H, Saksa JR, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry 2010;71: 463-474.
    • (2010) J Clin Psychiatry , vol.71 , pp. 463-474
    • Woods, S.W.1    Morgenstern, H.2    Saksa, J.R.3
  • 42
    • 28044470076 scopus 로고    scopus 로고
    • Patterns of prescription of four major antipsychotics: a retrospective study based on medical records of psychiatric inpatients
    • Gasquet I, Gury C, Tcherny-Lessenot S, Quesnot A, Gaudebout P. Patterns of prescription of four major antipsychotics: a retrospective study based on medical records of psychiatric inpatients. Pharmacoepidemiol Drug Saf 2005;14: 805-811.
    • (2005) Pharmacoepidemiol Drug Saf , vol.14 , pp. 805-811
    • Gasquet, I.1    Gury, C.2    Tcherny-Lessenot, S.3    Quesnot, A.4    Gaudebout, P.5
  • 43
    • 0024508606 scopus 로고
    • The course of tardive dyskinesia in patients on long-term neuroleptics
    • Bergen JA, Eyland EA, Campbell JA, et al. The course of tardive dyskinesia in patients on long-term neuroleptics. Br J Psychiatry 1989;154: 523-528.
    • (1989) Br J Psychiatry , vol.154 , pp. 523-528
    • Bergen, J.A.1    Eyland, E.A.2    Campbell, J.A.3
  • 44
    • 0021904890 scopus 로고
    • Tardive dyskinesia: reversible and irreversible
    • Casey DE. Tardive dyskinesia: reversible and irreversible. Psychopharmacology Suppl 1985;2: 88-97.
    • (1985) Psychopharmacology Suppl , vol.2 , pp. 88-97
    • Casey, D.E.1
  • 45
    • 0035957276 scopus 로고    scopus 로고
    • The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up
    • Fernandez HH, Krupp B, Friedman JH. The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up. Neurology 2001;56: 805-807.
    • (2001) Neurology , vol.56 , pp. 805-807
    • Fernandez, H.H.1    Krupp, B.2    Friedman, J.H.3
  • 46
    • 0025167627 scopus 로고
    • Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication
    • Glazer WM, Morgenstern H, Schooler N, Berkman CS, Moore DC. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br J Psychiatry 1990;157: 585-592.
    • (1990) Br J Psychiatry , vol.157 , pp. 585-592
    • Glazer, W.M.1    Morgenstern, H.2    Schooler, N.3    Berkman, C.S.4    Moore, D.C.5
  • 47
    • 0021184468 scopus 로고
    • The reversibility of "permanent" tardive dyskinesia
    • Klawans HL, Tanner CM, Barr A. The reversibility of "permanent" tardive dyskinesia. Clin Neuropharmacol 1984;7: 153-159.
    • (1984) Clin Neuropharmacol , vol.7 , pp. 153-159
    • Klawans, H.L.1    Tanner, C.M.2    Barr, A.3
  • 48
    • 39849090320 scopus 로고    scopus 로고
    • Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment
    • Modestin J, Wehrli MV, Stephan PL, Agarwalla P. Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment. Schizophr Res 2008;100: 97-107.
    • (2008) Schizophr Res , vol.100 , pp. 97-107
    • Modestin, J.1    Wehrli, M.V.2    Stephan, P.L.3    Agarwalla, P.4
  • 49
    • 84893052259 scopus 로고    scopus 로고
    • 64th Annual Meeting of the American Academy of Neurology, 2012, New Orleans, LA. Abstract
    • Zutshi D, Cloud L, Factor S. Reversibility of tardive syndromes. 64th Annual Meeting of the American Academy of Neurology, 2012, New Orleans, LA. Abstract.
    • Reversibility of tardive syndromes
    • Zutshi, D.1    Cloud, L.2    Factor, S.3
  • 50
    • 0019207526 scopus 로고
    • Changes in prevalence, severity, and recovery in tardive dyskinesia with age
    • Smith JM, Baldessarini RJ. Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Arch Gen Psychiatry 1980;37: 1368-1373.
    • (1980) Arch Gen Psychiatry , vol.37 , pp. 1368-1373
    • Smith, J.M.1    Baldessarini, R.J.2
  • 51
    • 0025727823 scopus 로고
    • The prediction of chronic persistent versus intermittent tardive dyskinesia. A retrospective follow-up study
    • Glazer WM, Morgenstern H, Doucette JT. The prediction of chronic persistent versus intermittent tardive dyskinesia. A retrospective follow-up study. Br J Psychiatry 1991;158: 822-828.
    • (1991) Br J Psychiatry , vol.158 , pp. 822-828
    • Glazer, W.M.1    Morgenstern, H.2    Doucette, J.T.3
  • 52
    • 0026466790 scopus 로고
    • A 10-year follow-up study of tardive dyskinesia
    • Yassa R, Nair NP. A 10-year follow-up study of tardive dyskinesia. Acta Psychiatr Scand 1992;86: 262-266.
    • (1992) Acta Psychiatr Scand , vol.86 , pp. 262-266
    • Yassa, R.1    Nair, N.P.2
  • 53
    • 0026454744 scopus 로고
    • Predictors of the course of tardive dyskinesia in patients receiving neuroleptics
    • Bergen J, Kitchin R, Berry G. Predictors of the course of tardive dyskinesia in patients receiving neuroleptics. Biol Psychiatry 1992;32: 580-594.
    • (1992) Biol Psychiatry , vol.32 , pp. 580-594
    • Bergen, J.1    Kitchin, R.2    Berry, G.3
  • 55
    • 0021165987 scopus 로고
    • Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures
    • Gardos G, Cole JO, Rapkin RM, et al. Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures. Arch Gen Psychiatry 1984;41: 1030-1035.
    • (1984) Arch Gen Psychiatry , vol.41 , pp. 1030-1035
    • Gardos, G.1    Cole, J.O.2    Rapkin, R.M.3
  • 56
    • 0019793974 scopus 로고
    • Effects of a six-week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics
    • Shenoy RS, Sadler AG, Goldberg SC, Hamer RM, Ross B. Effects of a six-week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics. J Clin Psychopharmacol 1981;1: 141-145.
    • (1981) J Clin Psychopharmacol , vol.1 , pp. 141-145
    • Shenoy, R.S.1    Sadler, A.G.2    Goldberg, S.C.3    Hamer, R.M.4    Ross, B.5
  • 57
    • 0018828867 scopus 로고
    • Covert dyskinesia in ambulatory schizophrenia
    • Carpenter WT, Rey AG, Stephens JH. Covert dyskinesia in ambulatory schizophrenia. Lancet 1980;2: 212-213.
    • (1980) Lancet , vol.2 , pp. 212-213
    • Carpenter, W.T.1    Rey, A.G.2    Stephens, J.H.3
  • 58
    • 0019367690 scopus 로고
    • Effects of gradual decrease and discontinuation of neuroleptics on clinical condition and tardive dyskinesia [proceedings]
    • Branchey MH, Branehey LB, Richardson MA. Effects of gradual decrease and discontinuation of neuroleptics on clinical condition and tardive dyskinesia [proceedings]. Psychopharmacol Bull 1981;17: 118-120.
    • (1981) Psychopharmacol Bull , vol.17 , pp. 118-120
    • Branchey, M.H.1    Branehey, L.B.2    Richardson, M.A.3
  • 60
    • 0028833128 scopus 로고
    • Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study
    • Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 1995;15: 36S-44S.
    • (1995) J Clin Psychopharmacol , vol.15
    • Chouinard, G.1
  • 61
    • 0344119568 scopus 로고    scopus 로고
    • Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study
    • Bai YM, Yu SC, Lin CC. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2003;64: 1342-1348.
    • (2003) J Clin Psychiatry , vol.64 , pp. 1342-1348
    • Bai, Y.M.1    Yu, S.C.2    Lin, C.C.3
  • 62
    • 77957857043 scopus 로고    scopus 로고
    • A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia
    • Chan HY, Chiang SC, Chang CJ, et al. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia. J Clin Psychiatry 2010;71: 1226-1233.
    • (2010) J Clin Psychiatry , vol.71 , pp. 1226-1233
    • Chan, H.Y.1    Chiang, S.C.2    Chang, C.J.3
  • 63
    • 84861338422 scopus 로고    scopus 로고
    • Improvement of tardive dyskinesia and dystonia associated with aripiprazole following a switch to quetiapine: case report and review of the literature
    • Ono S, Suzuki Y, Shindo M, et al. Improvement of tardive dyskinesia and dystonia associated with aripiprazole following a switch to quetiapine: case report and review of the literature. J Clin Pharm Ther 2012;37: 370-372.
    • (2012) J Clin Pharm Ther , vol.37 , pp. 370-372
    • Ono, S.1    Suzuki, Y.2    Shindo, M.3
  • 66
    • 33645798913 scopus 로고    scopus 로고
    • Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial
    • Huntington Study Group
    • Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006;66: 366-372.
    • (2006) Neurology , vol.66 , pp. 366-372
  • 67
    • 0032818966 scopus 로고    scopus 로고
    • Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol
    • Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry 1999;156: 1279-1281.
    • (1999) Am J Psychiatry , vol.156 , pp. 1279-1281
    • Ondo, W.G.1    Hanna, P.A.2    Jankovic, J.3
  • 68
    • 33847731495 scopus 로고    scopus 로고
    • Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders
    • Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007;22: 193-197.
    • (2007) Mov Disord , vol.22 , pp. 193-197
    • Kenney, C.1    Hunter, C.2    Jankovic, J.3
  • 69
    • 0031029072 scopus 로고    scopus 로고
    • Long-term effects of tetrabenazine in hyperkinetic movement disorders
    • Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997;48: 358-362.
    • (1997) Neurology , vol.48 , pp. 358-362
    • Jankovic, J.1    Beach, J.2
  • 70
    • 79955609673 scopus 로고    scopus 로고
    • Tetrabenazine for the treatment of tardive dyskinesia
    • Leung JG, Breden EL. Tetrabenazine for the treatment of tardive dyskinesia. Ann Pharmacother 2011;45: 525-531.
    • (2011) Ann Pharmacother , vol.45 , pp. 525-531
    • Leung, J.G.1    Breden, E.L.2
  • 71
    • 0019034630 scopus 로고
    • Evaluation of reserpine and alpha-methyldopa in the treatment of tardive dyskinesia
    • Huang CC, Wang RI, Hasegawa A, Alverno L. Evaluation of reserpine and alpha-methyldopa in the treatment of tardive dyskinesia. Psychopharmacol Bull 1980;16: 41-43.
    • (1980) Psychopharmacol Bull , vol.16 , pp. 41-43
    • Huang, C.C.1    Wang, R.I.2    Hasegawa, A.3    Alverno, L.4
  • 73
    • 33645872123 scopus 로고    scopus 로고
    • Tetrabenazine in the treatment of hyperkinetic movement disorders
    • Kenney C, Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother 2006;6: 7-17.
    • (2006) Expert Rev Neurother , vol.6 , pp. 7-17
    • Kenney, C.1    Jankovic, J.2
  • 74
    • 0019977930 scopus 로고
    • Palliative treatment of tardive dyskinesia with combination of amantadine-neuroleptic administration
    • Allen RM. Palliative treatment of tardive dyskinesia with combination of amantadine-neuroleptic administration. Biol Psychiatry 1982;17: 719-727.
    • (1982) Biol Psychiatry , vol.17 , pp. 719-727
    • Allen, R.M.1
  • 75
    • 0015239230 scopus 로고
    • Amantadine for dyskinesia tarda
    • Vale S, Espejel MA. Amantadine for dyskinesia tarda. N Engl J Med 1971;284: 673.
    • (1971) N Engl J Med , vol.284 , pp. 673
    • Vale, S.1    Espejel, M.A.2
  • 79
    • 0033999316 scopus 로고    scopus 로고
    • The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study
    • Snow BJ, Macdonald L, McAuley D, Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 2000;23: 82-85.
    • (2000) Clin Neuropharmacol , vol.23 , pp. 82-85
    • Snow, B.J.1    Macdonald, L.2    McAuley, D.3    Wallis, W.4
  • 80
    • 0026975680 scopus 로고
    • Studies on the mechanism of action of the antiparkinsonian drugs memantine and amantadine: no evidence for direct dopaminomimetic or antimuscarinic properties
    • Jackisch R, Link T, Neufang B, Koch R. Studies on the mechanism of action of the antiparkinsonian drugs memantine and amantadine: no evidence for direct dopaminomimetic or antimuscarinic properties. Arch Int Pharmacodyn Ther 1992;320: 21-42.
    • (1992) Arch Int Pharmacodyn Ther , vol.320 , pp. 21-42
    • Jackisch, R.1    Link, T.2    Neufang, B.3    Koch, R.4
  • 81
    • 0030995082 scopus 로고    scopus 로고
    • A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia
    • Angus S, Sugars J, Boltezar R, Koskewich S, Schneider NM. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol 1997;17: 88-91.
    • (1997) J Clin Psychopharmacol , vol.17 , pp. 88-91
    • Angus, S.1    Sugars, J.2    Boltezar, R.3    Koskewich, S.4    Schneider, N.M.5
  • 82
    • 78651415131 scopus 로고    scopus 로고
    • Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study
    • Pappa S, Tsouli S, Apostolou G, Mavreas V, Konitsiotis S. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol 2010;33: 271-275.
    • (2010) Clin Neuropharmacol , vol.33 , pp. 271-275
    • Pappa, S.1    Tsouli, S.2    Apostolou, G.3    Mavreas, V.4    Konitsiotis, S.5
  • 83
    • 44849130867 scopus 로고    scopus 로고
    • Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study
    • Woods SW, Saksa JR, Baker CB, Cohen SJ, Tek C. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2008;69: 546-554.
    • (2008) J Clin Psychiatry , vol.69 , pp. 546-554
    • Woods, S.W.1    Saksa, J.R.2    Baker, C.B.3    Cohen, S.J.4    Tek, C.5
  • 84
    • 0041623023 scopus 로고    scopus 로고
    • Levetiracetam as a treatment for tardive dyskinesia: a case report
    • McGavin CL, John V, Musser WS. Levetiracetam as a treatment for tardive dyskinesia: a case report. Neurology 2003;61: 419.
    • (2003) Neurology , vol.61 , pp. 419
    • McGavin, C.L.1    John, V.2    Musser, W.S.3
  • 85
    • 33646700970 scopus 로고    scopus 로고
    • Treatment of neuroleptic-induced tardive dyskinesia with levetiracetam: a case series
    • Bona JR. Treatment of neuroleptic-induced tardive dyskinesia with levetiracetam: a case series. J Clin Psychopharmacol 2006;26: 215-216.
    • (2006) J Clin Psychopharmacol , vol.26 , pp. 215-216
    • Bona, J.R.1
  • 86
    • 33748346041 scopus 로고    scopus 로고
    • Levetiracetam in tardive dyskinesia: an open label study
    • Konitsiotis S, Pappa S, Mantas C, Mavreas V. Levetiracetam in tardive dyskinesia: an open label study. Mov Disord 2006;21: 1219-1221.
    • (2006) Mov Disord , vol.21 , pp. 1219-1221
    • Konitsiotis, S.1    Pappa, S.2    Mantas, C.3    Mavreas, V.4
  • 88
    • 78651241450 scopus 로고    scopus 로고
    • Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial
    • Wolz M, Lohle M, Strecker K, et al. Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial. J Neural Transm 2010;117: 1279-1286.
    • (2010) J Neural Transm , vol.117 , pp. 1279-1286
    • Wolz, M.1    Lohle, M.2    Strecker, K.3
  • 90
    • 34548316587 scopus 로고    scopus 로고
    • Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study
    • Libov I, Miodownik C, Bersudsky Y, Dwolatzky T, Lerner V. Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry 2007;68: 1031-1037.
    • (2007) J Clin Psychiatry , vol.68 , pp. 1031-1037
    • Libov, I.1    Miodownik, C.2    Bersudsky, Y.3    Dwolatzky, T.4    Lerner, V.5
  • 92
    • 84870318173 scopus 로고    scopus 로고
    • Propranolol therapy for tardive dyskinesia revisited
    • Factor SA. Propranolol therapy for tardive dyskinesia revisited. Mov Disord 2012;27: 1703.
    • (2012) Mov Disord , vol.27 , pp. 1703
    • Factor, S.A.1
  • 93
    • 0018901839 scopus 로고
    • Low-dose propranolol in tardive dyskinesia
    • Bacher NM, Lewis HA. Low-dose propranolol in tardive dyskinesia. Am J Psychiatry 1980;137: 495-497.
    • (1980) Am J Psychiatry , vol.137 , pp. 495-497
    • Bacher, N.M.1    Lewis, H.A.2
  • 94
    • 0020598144 scopus 로고
    • Propranolol in the treatment of tardive-dyskinesia
    • Perenyi A, Farkas A. Propranolol in the treatment of tardive-dyskinesia. Biol Psychiatry 1983;18: 391-394.
    • (1983) Biol Psychiatry , vol.18 , pp. 391-394
    • Perenyi, A.1    Farkas, A.2
  • 98
    • 0033428455 scopus 로고    scopus 로고
    • Vitamin B6 in treatment of tardive dyskinesia: a preliminary case series study
    • Lerner V, Kaptsan A, Miodownik C, Kotler M. Vitamin B6 in treatment of tardive dyskinesia: a preliminary case series study. Clin Neuropharmacol 1999;22: 241-243.
    • (1999) Clin Neuropharmacol , vol.22 , pp. 241-243
    • Lerner, V.1    Kaptsan, A.2    Miodownik, C.3    Kotler, M.4
  • 99
    • 37049021960 scopus 로고    scopus 로고
    • Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study
    • Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study. J Clin Psychiatry 2007;68: 1648-1654.
    • (2007) J Clin Psychiatry , vol.68 , pp. 1648-1654
    • Lerner, V.1    Miodownik, C.2    Kaptsan, A.3
  • 100
    • 79959266946 scopus 로고    scopus 로고
    • Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial
    • Zhang WF, Tan YL, Zhang XY, Chan RC, Wu HR, Zhou DF. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011;72: 615-621.
    • (2011) J Clin Psychiatry , vol.72 , pp. 615-621
    • Zhang, W.F.1    Tan, Y.L.2    Zhang, X.Y.3    Chan, R.C.4    Wu, H.R.5    Zhou, D.F.6
  • 101
    • 0032899317 scopus 로고    scopus 로고
    • Branched chain amino acids decrease tardive dyskinesia symptoms
    • Richardson MA, Bevans ML, Weber JB, et al. Branched chain amino acids decrease tardive dyskinesia symptoms. Psychopharmacology (Berl) 1999;143: 358-364.
    • (1999) Psychopharmacology (Berl) , vol.143 , pp. 358-364
    • Richardson, M.A.1    Bevans, M.L.2    Weber, J.B.3
  • 103
    • 0038149630 scopus 로고    scopus 로고
    • Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men
    • Richardson MA, Bevans ML, Read LL, et al. Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. Am J Psychiatry 2003;160: 1117-1124.
    • (2003) Am J Psychiatry , vol.160 , pp. 1117-1124
    • Richardson, M.A.1    Bevans, M.L.2    Read, L.L.3
  • 104
    • 77954953999 scopus 로고    scopus 로고
    • Lingual protrusion dystonia: frequency etiology and botulinum toxin therapy
    • Esper CD, Freeman A, Factor SA. Lingual protrusion dystonia: frequency etiology and botulinum toxin therapy. Park Rel Disord 2010;16: 438-441.
    • (2010) Park Rel Disord , vol.16 , pp. 438-441
    • Esper, C.D.1    Freeman, A.2    Factor, S.A.3
  • 105
  • 106
    • 49849086653 scopus 로고    scopus 로고
    • Successful treatment of tardive lingual dystonia with botulinum toxin: case report and review of the literature
    • Hennings JM, Krause E, Botzel K, Wetter TC. Successful treatment of tardive lingual dystonia with botulinum toxin: case report and review of the literature. Prog Neuropsychopharmacol Biol Psychiatry 2008;32: 1167-1171.
    • (2008) Prog Neuropsychopharmacol Biol Psychiatry , vol.32 , pp. 1167-1171
    • Hennings, J.M.1    Krause, E.2    Botzel, K.3    Wetter, T.C.4
  • 109
    • 33846855983 scopus 로고    scopus 로고
    • Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia
    • Damier P, Thobois S, Witjas T, et al. Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia. Arch Gen Psychiatry 2007;64: 170-176.
    • (2007) Arch Gen Psychiatry , vol.64 , pp. 170-176
    • Damier, P.1    Thobois, S.2    Witjas, T.3
  • 110
    • 4544307741 scopus 로고    scopus 로고
    • Unilateral deep brain stimulation of the internal globus pallidus alleviates tardive dyskinesia
    • Schrader C, Peschel T, Petermeyer M, Dengler R, Hellwig D. Unilateral deep brain stimulation of the internal globus pallidus alleviates tardive dyskinesia. Mov Disord 2004;19: 583-585.
    • (2004) Mov Disord , vol.19 , pp. 583-585
    • Schrader, C.1    Peschel, T.2    Petermeyer, M.3    Dengler, R.4    Hellwig, D.5
  • 111
    • 33744486879 scopus 로고    scopus 로고
    • Deep brain stimulation in the treatment of tardive dystonia
    • Zhang JG, Zhang K, Wang ZC. Deep brain stimulation in the treatment of tardive dystonia. Chin Med J (Engl) 2006;119: 789-792.
    • (2006) Chin Med J (Engl) , vol.119 , pp. 789-792
    • Zhang, J.G.1    Zhang, K.2    Wang, Z.C.3
  • 112
  • 113
    • 0027534918 scopus 로고
    • The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity
    • Gerlach J, Korsgaard S, Clemmesen P, et al. The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatr Scand 1993;87: 244-252.
    • (1993) Acta Psychiatr Scand , vol.87 , pp. 244-252
    • Gerlach, J.1    Korsgaard, S.2    Clemmesen, P.3
  • 114
    • 0022932306 scopus 로고
    • Natural history and treatment of tardive dystonia
    • Kang UJ, Burke RE, Fahn S. Natural history and treatment of tardive dystonia. Mov Disord 1986;1: 193-208.
    • (1986) Mov Disord , vol.1 , pp. 193-208
    • Kang, U.J.1    Burke, R.E.2    Fahn, S.3
  • 115
    • 84866601685 scopus 로고    scopus 로고
    • Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba
    • Zhang XY, Zhang WF, Zhou DF, et al. Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba. Biol Psychiatry 2012;72: 700-706.
    • (2012) Biol Psychiatry , vol.72 , pp. 700-706
    • Zhang, X.Y.1    Zhang, W.F.2    Zhou, D.F.3
  • 116
    • 0034061290 scopus 로고    scopus 로고
    • Tardive dyskinesia: pathophysiology and animal models
    • Casey DE. Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry 2000;61(Suppl.4: 5-9.
    • (2000) J Clin Psychiatry , vol.61 , Issue.SUPPL. 4 , pp. 5-9
    • Casey, D.E.1
  • 117
    • 31544451267 scopus 로고    scopus 로고
    • Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction
    • Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J Psychiatry 2005;50: 541-547.
    • (2005) Can J Psychiatry , vol.50 , pp. 541-547
    • Margolese, H.C.1    Chouinard, G.2    Kolivakis, T.T.3    Beauclair, L.4    Miller, R.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.